A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00505388

Enrollment

5137

Registered

2007-07-23

Start date

2007-07-31

Completion date

2010-04-30

Last updated

2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial Asthma

Keywords

asthma, bronchial, Symbicort

Brief summary

This patient follow-up programme was designed to describe the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy in routine clinical practice in comparison with the already documented use of Symbicort as maintenance and reliever therapy in clinical therapies

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this programme * signed and dated informed consent(ICF) * for patients under-age, signed and dated ICF form from both the patient and the patient's parent/legal guardian is required

Exclusion criteria

* Involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)

Countries

Belgium, Bulgaria, Czechia, Denmark, Germany, Greece, Hungary, Netherlands, Norway, Portugal, Sweden, United Kingdom

Outcome results